#PMR and Telemedicine: do we really need an office visit? Can we use a synchronous audiovisual visit or a rheumatology eConsult to evaluate the patient's symptoms quickly? Does it allow us to make an accurate diagnosis? https://t.co/JTAYstzDk8 https://t.co/NNvYfdkm2K

CMAJ analysis of 28 studies & 24 million pts Rx opioids suggest a higher risk of opioid overdose w/: high-dose opioids, fentanyl, multiple opioid Rxs, overdose Hx, Dx of substance use, depression, bipolar, mental illness, pancreatitis https://t.co/FprgoaTvXR https://t.co/G0QjNJTezu

#PMR Polymyalgia rheumatica is very common, yet there is little research on the Dx & Management of PMR by #PCPs! Mayo study prevalence 701 per 100,000 (women=870 and men =508 per 100,000 population). https://t.co/7JZFeRPRnn https://t.co/0JoaXL4qv0

RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. https://t.co/Wdk4tvnlRz https://t.co/YFdvfbyrpJ

Unpopular opinion: spinach can be bad for you The title might have misled you; simply, Dr Stephen Paget’s analogy comparing the drastic response to steroids in #PMR to Popeye’s spinach stuck with me! https://t.co/VNlY6O5YeE https://t.co/RZmbVL2EiZ

Methotrexate in OA Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more. https://t.co/RHiRBxajc6 https://t.co/PCygEXKT8f

Subcutaneous Remsima, an infliximab biosimilar, has been FDA. Celltrion has rebranded this as Zymfentra, for maintenance therapy in adults with moderately to severely active Ulcerative colitis and Crohn's disease following (after giving IV infliximab) https://t.co/gvcssRuB92 https://t.co/dPYVi10KIA

Korean Insurance matched (1:10) claims cohort study (2010-2017) found bronchiectasis in 5.3% of 4845 systemic sclerosis pts vs 1.9% of non-SSc controls (24,225). SSc pts have a signif higher risk of bronchiectasis (adj HR 2.63), thus a minor feature of SSc https://t.co/7oOBkpw2DM https://t.co/683I0mMmQI

What Goes Wrong with the Immune System in #PMR? Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease. Imaging studies have revealed that PMR should not be viewed as a mysterious source of pain and stiffness. https://t.co/bQDcpM1ymQ https://t.co/B5anJolukY

#PMR TNR Pearls Lessons learned from this months Tuesday Nite Rheumatology (TNR) sessions. https://t.co/HiYcHL52hO https://t.co/z0xuYODLXV

FDA Approves Bimekizumab for Plaque Psoriasis UCB announced today that the FDA has approved bimekizumab-bkzx (Bimzelx)) for the treatment of moderate to severe plaque psoriasis in adults who needing systemic therapy or phototherapy. https://t.co/BqeSAAxtQb https://t.co/LFjzkmAC5w

Using Methotrexate in #PMR Where in other inflammatory rheumatic disorders, such as RA and PsA, early initiation of MTX is common practice, this is not the case in PMR. Treatment of PMR is still largely based on GC. https://t.co/fW9BL3YWS5 https://t.co/bQwozOPUvJ